Deal value in pharma industry decreases by 67.2 per cent in August: Globalata

The latest GlobalData report has revealed that the pharmaceutical industry reported 56 deals worth $11.7 billion last month as compared to the last 12-month average (August 2020 to July 2021) of 104 deals worth $28.9 billion.

According to the report, Sanofi, to acquire Translate Bio Inc for a consideration of $3.2 billion; Pfizer to acquire Trillium Therapeutics for an implied value of $2.3 billion; and Bayer AG to acquire Vividion Therapeutics Inc, targets for $2 billion, were the three major deals that contributed 63.2 per cent of the total deal value during August 2021.

It also said that the industry reported 109 venture capital (VC) deals worth $4.5 billion in August 2021, compared to the last 12-month average (August 2020 to July 2021) of 171 deals worth $5.1 billion.

Further, the statement said that Suzhou Abogen Biosciences, raising $700 million in series C round to advance mRNA COVID-19 vaccine; Laronde, raising $440 million in series B financing to advance the development of its eRNA platform; and XtalPi, raising $400 million in series D financing to accelerate drug discovery, were the three major VC deals reported in August 2021.